Invited Commentary: Achieving Post-Bypass Hemostasis in Young Children: At What Cost?

Area of Science:

• Pediatric Cardiac Surgery
• Hematology
• Critical Care Medicine

Background:

• Young children undergoing cardiopulmonary bypass frequently develop coagulopathy, leading to significant postoperative blood loss.
• Increased bleeding and blood product transfusions post-bypass are linked to adverse outcomes in pediatric patients.
• Current rescue therapies, including prothrombin complex concentrates (PCCs) and recombinant activated factor VII, are used off-label for refractory bleeding.

Purpose of the Study:

• To review the current literature on the safety and efficacy of PCCs in neonates and young children undergoing cardiac surgery.
• To highlight the limitations of existing studies, which are often retrospective, single-center, and lack standardized protocols.
• To emphasize the need for well-designed multicenter randomized controlled trials to establish optimal dosing and risk-benefit profiles for PCCs.

Main Methods:

• Review of existing retrospective and observational studies on PCC use in pediatric cardiac surgery.
• Analysis of concerns regarding thrombotic events associated with PCCs, particularly Factor VIII inhibitor bypassing activity (FEIBA).
• Identification of the lack of validated in vivo assays for efficacy measurement and dose titration.

Main Results:

• Existing studies on PCCs in pediatric cardiac surgery are limited by small sample sizes, retrospective designs, and variable administration protocols.
• There are significant concerns about thrombotic risks with PCCs, especially FEIBA, in a population already at risk for postoperative thromboembolism.
• Currently, there is no validated method to measure FEIBA efficacy in vivo for dose adjustments.

Conclusions:

• The efficacy and safety of PCCs in pediatric cardiac surgery remain uncertain due to the limitations of current evidence.
• Multicenter randomized controlled trials are essential to determine the optimal use and risk-benefit of PCCs in this population.
• Until robust data are available, the decision to administer procoagulants should carefully weigh the risks of bleeding against the potential for thrombotic complications.